Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.34 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9590130 | 0.98 | PTGS1 (0.43) | PTGS1SLC7A11TSHRALDH1A1SLC7A5 | |
| SCHEMBL564046 | 0.80 | TSHR (0.48) | TSHRALDH1A1SLC7A5SMN1; SMN2SLC1A3 | |
| SCHEMBL7359844 | 0.80 | SLC7A5 (0.54) | TSHRALDH1A1SLC7A5ANPEPERAP1 | |
| SCHEMBL21673199 | 0.80 | TSHR (0.43) | TSHRALDH1A1SLC7A5SMN1; SMN2SLC1A3 | |
| SCHEMBL16086739 | 0.80 | TSHR (0.43) | TSHRALDH1A1SLC7A5SMN1; SMN2SLC1A3 | |
| SCHEMBL4762688 | 0.80 | SLC7A5 (0.54) | TSHRALDH1A1SLC7A5ANPEPERAP1 | |
| SCHEMBL19028007 | 0.80 | TSHR (0.48) | TSHRALDH1A1SLC7A5SMN1; SMN2SLC1A3 | |
| SCHEMBL563054 | 0.80 | TSHR (0.48) | TSHRALDH1A1SLC7A5SMN1; SMN2SLC1A3 | |
| SCHEMBL23408840 | 0.79 | PTGS1 (0.41) | PTGS1SLC7A11ALDH1A1SLC7A5ENPEP | |
| SCHEMBL17659959 | 0.79 | TSHR (0.39) | TSHRALDH1A1SLC7A5SMN1; SMN2SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0546063-A1 | TOXIC AGENT PROTECTIVE COMPOUNDS, COMPOSITIONS AND USES | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) | 1993-06-16 | — | — | EP | claimed |
| WO-1992004024-A2 | TOXIC AGENT PROTECTIVE COMPOUNDS, COMPOSITIONS AND METHOD | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1992-03-19 | — | — | WO | claimed |
| US-11236102-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200325151-A1 | OXABICYCLOHEPTANE PRODRUGS | LIXTE BIOTECHNOLOGY, INC. | 2020-10-15 | — | — | US | disclosed |
| US-10364252-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-9988394-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988394-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20040122099-A1 | Process for preparing S-(2-aminoethyl)-2-methyl-L-cysteine | WUTS PETER GUILLAUME MARIE (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004039772-A1 | PROCESS FOR PREPARING S-(2-AMINOETHYL)-2-METHYL-L-CYSTEINE | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-05-13 | — | — | WO | disclosed |
| EP-0546063-A1 | TOXIC AGENT PROTECTIVE COMPOUNDS, COMPOSITIONS AND USES | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) | 1993-06-16 | — | — | EP | disclosed |
| WO-1992004024-A2 | TOXIC AGENT PROTECTIVE COMPOUNDS, COMPOSITIONS AND METHOD | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325151-A1 | OXABICYCLOHEPTANE PRODRUGS | UGT2B7, UGT1A6, UGT1A1 | PTGS1 1549/4885SLC7A11 420/4885TSHR 1135/4885 |
| US-20040122099-A1 | Process for preparing S-(2-aminoethyl)-2-methyl-L-cysteine | MGMT, CBS, BHMT2 | PTGS1 2288/4885SLC7A11 49/4885TSHR 4264/4885 |
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | UGT2B7, UGT1A6, UGT1A1 | PTGS1 1549/4885SLC7A11 420/4885TSHR 1135/4885 |
| US-10364252-B2 | Oxabicycloheptane prodrugs | UGT2B7, UGT1A6, UGT1A1 | PTGS1 1549/4885SLC7A11 420/4885TSHR 1135/4885 |
| US-11236102-B2 | Oxabicycloheptane prodrugs | UGT2B7, UGT1A6, UGT1A1 | PTGS1 1549/4885SLC7A11 420/4885TSHR 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.